Takeaway

• More than 28% of patients with cardiac implantable electronic devices (CIEDs) experience subclinical atrial fibrillation (SCAF) and resultant higher risk for several bad outcomes.
• Authors call for more research into the use of oral anticoagulants in these patients.

Why this matters

• SCAF refers to atrial high-rate episodes (AHREs) in patients...